semaglutide mc4r deficiency
The Hidden Price of Semaglutide: 3 Critical Risks
Semaglutide offers strong weight-loss results, but patients with MC4R-deficient obesity face three major risks: gastrointestinal intolerance, limited long-term adherence, and high out-of-pocket costs. In the Phase III OASIS 4 trial, the oral Wegovy pill produced a mean 16.6% weight loss among participants with MC4R deficiency, highlighting its potency while